Abstract
Parkinson’s disease (PD) is a neurological disorder caused by progressive degeneration of dopaminergic neurons in the nigrostriatal area of the brain. The decrease in dopamine (DA) neurotransmitter levels in the striatum and substantia nigra pars compacta is a neurochemistry hallmark of PD. Therefore, determination of dopamine and its metabolites levels in biological samples provides an important key to understanding the neurochemistry profile of PD. This chapter describes the use of reversed-phase HPLC with electrochemical detection (ECD) for simultaneously measuring monoamine neurotransmitters, including dopamine and its metabolites, norepinephrine as well as serotonin and its metabolite. ECD provides an ultrasensitive measurement, which detects at the picogram level. One run for each sample finishes within 18 min, shows clear chromatographic peaks and a complete separation, and produces excellent precision and reproducibility. Once set up, HPLC-ECD is economic and efficient for analyzing a large number of samples. This method has been broadly used for analyzing a variety of biological samples, such as cerebrospinal fluids, plasma, microdialysis elutes, tissues, and cultured cells. In recent days, it has been reported to be able to detect the dopamine level in a single drosophila head.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dauer, W. & Przedborski, S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39, 889–909.
O’Neill, R. D. (2005) Long-term monitoring of brain dopamine metabolism in vivo with carbon paste electrodes. Sensors 5, 317–342.
Peuler, J. D. & Johnson, G. A. (1977) Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21, 625–36.
Commissiong, J. W. (1983) Mass fragmentographic analysis of monoamine metabolites in the spinal cord of rat after the administration of morphine. J Neurochem 41, 1313–8.
Yoshitake, T., Kehr, J., Todoroki, K., Nohta, H. & Yamaguchi, M. (2006) Derivatization chemistries for determination of serotonin, norepinephrine and dopamine in brain microdialysis samples by liquid chromatography with fluorescence detection. Biomed Chromatogr 20, 267–81.
Wei, D., Bailey, M. J., Andrew, P. & Ryhanen, T. (2009) Electrochemical biosensors at the nanoscale. Lab Chip 9, 2123–31.
Kalita, J., Kumar, S., Vijaykumar, K., Palit, G. & Misra, U. K. (2007) A study of CSF catecholamine and its metabolites in acute and convalescent period of encephalitis. J Neurol Sci 252, 62–6.
Mefford, I. N., Ward, M. M., Miles, L., Taylor, B., Chesney, M. A., Keegan, D. L. & Barchas, J. D. (1981) Determination of plasma catecholamines and free 3,4-dihydroxyphenylacetic acid in continuously collected human plasma by high performance liquid chromatography with electrochemical detection. Life Sci 28, 477–83.
Middlemiss, D. N. & Hutson, P. H. (1990) Measurement of the in vitro release of endogenous monoamine neurotransmitters as a means of identification of prejunctional receptors. J Neurosci Methods 34, 23–8.
Yang, L., Calingasan, N. Y., Chen, J., Ley, J. J., Becker, D. A. & Beal, M. F. (2005) A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp Neurol 191, 86–93.
Roy, N. S., Cleren, C., Singh, S. K., Yang, L., Beal, M. F. & Goldman, S. A. (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12, 1259–68.
Yang, Y., Ouyang, Y., Yang, L., Beal, M. F., McQuibban, A., Vogel, H. & Lu, B. (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 105, 7070–5.
Koshiishi, I., Mamura, Y., Liu, J. & Imanari, T. (1998) Evaluation of an acidic deproteinization for the measurement of ascorbate and dehydroascorbate in plasma samples. Clin Chem 44, 863–8.
Sakuma, R., Nishina, T. & Kitamura, M. (1987) Deproteinizing methods evaluated for determination of uric acid in serum by reversed-phase liquid chromatography with ultraviolet detection. Clin Chem 33, 1427–30.
Acknowledgments
We would like to acknowledge the support of NIA NS39258 and the Parkinson’s Disease Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Yang, L., Beal, M.F. (2011). Determination of Neurotransmitter Levels in Models of Parkinson’s Disease by HPLC-ECD. In: Manfredi, G., Kawamata, H. (eds) Neurodegeneration. Methods in Molecular Biology, vol 793. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-328-8_27
Download citation
DOI: https://doi.org/10.1007/978-1-61779-328-8_27
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-327-1
Online ISBN: 978-1-61779-328-8
eBook Packages: Springer Protocols